{
    "nctId": "NCT00267553",
    "briefTitle": "Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer",
    "officialTitle": "Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Neoplasms, Neoplasms, Hormone-Dependent",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "In conjunction with the data from Biomed 777-CLP-29, compare the time to progression (TTP) in the atamestane plus toremifene arm to the TTP in the letrozole plus placebo arm",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* To be eligible to receive continued treatment, subjects must remain eligible to receive study drug at the time of their last Biomed 777-CLP-29 visit\n* To continue on survival follow-up, subjects must be in survival follow-up in study Biomed 777-CLP-29\n* Written informed consent obtained for subjects who continue study drug treatment\n\nExclusion Criteria:\n\n* Subjects who have withdrawn consent to participate in Biomed 777-CLP-29 for any reason\n* Subjects for whom the investigator considers study participation is no longer in the best interest of those subjects.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}